A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies

Inclusion Criteria: * Age is over 18 years old * Histologically or cytologically diagnosed patients with recurrent or refractory B-cell malignancies * ECOG performance status (PS) 0 \~ 1 * Expected survival of \> or = 3 months Exclusion Criteria: * The use of PI3Ks as the target of anti-tumor drugs progress (due to intolerance group) * Received any other anti-cancer treatment within 4 weeks * Unable to swallow, chronic diarrhea and intestinal obstruction, there are many factors that affect drug use and absorption * Allergy, or known to have a history of allergy to the drug components